Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Trends in Molecular Medicine|March 4, 2011
Targeting mutant fibroblast growth factor receptors in cancerHeidi Greulich, Pamela M PollockFuture Oncology (London, England)|February 27, 2009
FGFR2 as a molecular target in endometrial cancerSara A Byron, Pamela M PollockCancer Discovery|December 12, 2012
Lineage-specific biomarkers predict response to FGFR inhibitionDavid C Loch, Pamela M PollockCancer Cell|August 2, 2002
A genome-based strategy uncovers frequent BRAF mutations in melanomaPamela M Pollock, Paul S MeltzerCancer Discovery|April 8, 2015
Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR AgentsLeisl M Packer, Pamela M PollockMethods in Molecular Biology (Clifton, N.J.)|April 27, 2024
Development and Expansion of Patient-Derived Xenografts for Endometrial CancerAsmerom T Sengal, Pamela M PollockInternational Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2012
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cellsSara A Byron, David C Loch, Pamela M PollockAnti-Cancer Drugs|October 13, 2012
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenograftsNicole A Doudican, Sara A Byron, Pamela M Pollock, et al.Cancers|April 30, 2021
Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial CancerAsmerom T Sengal, Deborah Smith, Rebecca Rogers, et al.Human Reproduction (Oxford, England)|February 21, 2008
Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis riskZhen Zhen Zhao, Pamela M Pollock, Shane Thomas, et al.Pageof 6